Table 1.
Clinical characteristics of IgAN patients with CKD stage 3 with different eGFR (mL/min/per 1.73m2).
Table 2.
Pathological characteristics of IgAN patients with CKD stage 3 with different eGFR (mL/min/per 1.73m2).
Table 3.
Hazard ratios and 95% confidence intervals for the composite endpoints in IgAN patients with CKD stage 3 with different eGFR.
Fig 1.
Hazard ratios of composite endpoints in IgAN patients with CKD stage 3 with different eGFR.
The reference was eGFR 55–60 mL/min/per 1.73 m2. The number of patients in each group was as follows: 55 to < 60: n = 70; 50 to <55: n = 77; 45 to < 50: n = 63; 40 to < 45: n = 67; 35 to < 40: n = 58; 30 to < 35: n = 55. HRs adjusted for age, sex, systolic blood pressure, diastolic blood pressure and proteinuria. Dots represent statistical significance, triangles represent non-significance, and squares represents the reference. Composite endpoints: doubling of serum creatinine, ESRD, or all-cause mortality. Abbreviations: IgAN, IgA nephropathy; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratios.
Table 4.
Clinical characteristics of IgAN patients with CKD stage G3a and G3b.
Table 5.
Pathological characteristics of IgAN patients with CKD stage G3a and G3b.
Fig 2.
Survival curves of IgAN patients with CKD stage 3 and patients of different subgroups.
(a) Patients with CKD stage 3. (b) Patients with CKD stage G3a (dotted line) or G3b (solid line) (log-rank P<0.001). Patients with G3a (dotted line) or G3b stage (solid line) based on (c) hypertension (G3a: n = 92, G3b: n = 98) (log-rank P<0.001), (d) non-hypertension (G3a: n = 117, G3b: n = 83) (log-rank P<0.001), (e) proteinuria ≥3.5 g/d (G3a: n = 48, G3b: n = 56) (log-rank P<0.001), (f) proteinuria< 3.5 g/d (G3a: n = 161, G3b: n = 125) (log-rank P<0.001), (g) anemia (G3a: n = 51, G3b: n = 64) (log-rank P<0.001), (h) non-anemia (G3a: n = 158, G3b: n = 117) (log-rank P<0.001), (i) serum phosphorus ≥1.45 mmol/L (G3a: n = 33, G3b: n = 67) (log-rank P<0.001), (j) serum phosphorus <1.45 mmol/L (G3a: n = 176, G3b: n = 114) (log-rank P<0.001). Abbreviations: IgAN, IgA nephropathy; CKD, chronic kidney disease.
Table 6.
Composite endpoints of univariate/multivariate Cox proportional hazards model analysis of IgAN patients with CKD stage 3.